Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
NCT06671912 · Alliance for Clinical Trials in Oncology · PHASE3 · suspended · last registry update 2026-09-02 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Amending protocol to increase sample size” | – | Registry record, Alliance for Clinical Trials in Oncology |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP19A1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-26Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., HRS-6209 + Letrozole + Dalpciclib/Palbociclib + Letrozole/Anastrozole (NCT07894328)
- 2026-09-25Results posted on the registry: Dartmouth-Hitchcock Medical Center, 17B-estradiol + Letrozole (NCT02188745)
- 2026-08-07Results posted on the registry: Priscilla McAuliffe, Tamoxifen + Anastrozole (NCT02206984)
- 2026-07-15Results posted on the registry: Pfizer, PF-07220060 + letrozole (NCT06465368)
- 2026-07-10Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-10Also stopped (terminated): Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-08Results posted on the registry: Novartis Pharmaceuticals, Ribociclib Placebo + Ribociclib (NCT03671330)
- 2026-07-02Results posted on the registry: Dana-Farber Cancer Institute, Abemaciclib + Tamoxifen (NCT06001762)
- 2026-06-25Also stopped (terminated): SOLTI Breast Cancer Research Group, Ribociclib + Letrozole OR Fulvestrant + Palbociclib + Letrozole OR Fulvestrant (NCT05207709)
- 2026-06-22Also stopped (withdrawn): Novartis Pharmaceuticals, ERW316 + Fulvestrant (NCT07570966)
- 2026-06-04Also stopped (terminated): University of Washington, Letrozole (NCT05183828)
- 2026-05-14Results posted on the registry: EQRx, Inc., Lerociclib + Letrozole or Fulvestrant (NCT05085002)
- 2026-05-14Also stopped (terminated): EQRx, Inc., Lerociclib + Letrozole or Fulvestrant (NCT05085002)
- 2026-04-15Results posted on the registry: University of Maryland, Baltimore, Anastrozole + Letrozole (NCT02095184)
- 2026-04-15Also stopped (terminated): University of Maryland, Baltimore, Anastrozole + Letrozole (NCT02095184)
- 2026-03-25Phase 3 first posted: BeOne Medicines, BGB-43395 + Letrozole (NCT07492641)
- 2026-03-16Results posted on the registry: University of Texas Southwestern Medical Center, Letrozole (NCT03747042)
- 2026-03-12Results posted on the registry: Spanish Breast Cancer Research Group, Doxorubicin + Cyclophosphamide (NCT04293393)
- 2026-03-11Results posted on the registry: Qamar Khan, Letrozole + Ribociclib (NCT02712723)
- 2026-02-24Results posted on the registry: Mayo Clinic, Anastrozole + Denifanstat (NCT03179904)
- 2026-02-24Also stopped (terminated): Sanofi, Amcenestrant + Fulvestrant (NCT04059484)
- 2026-02-24Results posted on the registry: City of Hope Medical Center, Fulvestrant + Letrozole (NCT02778685)
- 2026-02-12Results posted on the registry: Alliance Foundation Trials, LLC., palbociclib + trastuzumab (NCT02947685)
- 2026-02-12Also stopped (withdrawn): Danish Breast Cancer Cooperative Group, Trastuzumab deruxtecan (T-DXd) + Ribociclib with ET (NCT06585969)
- 2026-02-10Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Ribociclib plus aromatase inhibitor + Aromatase inhibitor (NCT07400523)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision